July 18, 2017 / 9:18 PM / in 5 months

BRIEF-Helix Biopharma and Moffitt Cancer Center to investigate L-DOS47 and checkpoint blockade

July 18 (Reuters) - Helix Biopharma Corp

* Helix Biopharma Corp and Moffitt Cancer Center to investigate L-DOS47 and checkpoint blockade

* Helix Biopharma -L-DOS47 therapy provides alternative pharmacologic approach to neutralizing tumor acidity that may improve response of immune checkpoint inhibitors Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below